https://www.selleckchem.com/pr....oducts/avelestat-azd
Infectious complications diminished from 25% to 16.4% (-6.1, 95%CI -11.5 to-0.7), reoperations from 8.1% to 6.1% (-2.2, 95%CI -5.1 to+0.6), median length of stay from 11 [IQR 8-18] to 8 [7-12] days (p0.001), hospital readmission from 14.1% to 8.9% (-5.4, 95%CI -9.6 to-1.1), mortality from 7.9% to 4.8% (-2.4, 95%CI -4.7 to-0.01), and failure-to rescue from 62.7% to 32.7% (-23.1, 95%CI -37.7 to-8.5). Implementation of a PBM program was associated with a reduction in transfusion rate and improvement in postoperative outcomes